Relationship between cardiac arrhythmias and anticancer therapy
https://doi.org/10.15829/1728-8800-2020-2417
Abstract
Cardiotoxicity is a widespread complication of anticancer therapy. One of the most difficult manifestations of cardiotoxicity is cardiac arrhythmias. The incidence of arrhythmias in cancer patients has not been fully established because most studies had insufficient number of patients. Establishing a causal relationship between anticancer drugs and specific arrhythmias also presents certain difficulties. The purpose of this review is to analyze the modern data on the incidence and clinical course of arrhythmias in patients taking anticancer therapy.
About the Authors
V. I. Potievskaya
P. Hertsen Moscow Oncology Research Institute, Branch of the National Medical Research Radiological Center
Russian Federation
Russian Federation
Moscow
A. A. Akhobekov
Lapino Clinical Hospital
Russian Federation
Russian Federation
Lapino. Moscow Oblast
E. V. Kononova
P. Hertsen Moscow Oncology Research Institute, Branch of the National Medical Research Radiological Center
Russian Federation
Russian Federation
Moscow
References
1. Matskeplishvili ST, Potievskaya VI, Popovkina OE, et al. Cardiovascular complications of oncology treatment (cardiooncology): prevention, diagnosis, treatment — the consensus of experts.Technologies of living systems. 2018;15(6):3-35. (In Russ.) doi:10.18127/j20700997-201806-01.
2. 2016 ESC position paper on cancer treatments and cardiovascular 13. toxicity developed under the auspices of the ESC committee for practice guidelines. Russ J Cardiol. 2017;(3):105-139. (In Russ.) doi: 10.15829/1560-4071-2017-3-105-139.
3. Krikunova OV, Vasyuk YA, Viskov RV, et al. Chemotherapy cardiotoxicity screening with cardiac troponins. Russian J Cardiol. 2015;(12):119-25. (In Russ.) doi:10.15829/1560-4071-2015-12-119-125.
4. Balluzek MF, Ionova AK. Cardio-oncology in treatment and rehabilitation programs of oncological patients. Russian J Cardiol. 2014;(5):75-80. (In Russ.) doi:10.15829/1560-4071-2014-5-75-80.
5. Snegovoj AV, Vicenya MV, Kopp MV, Larionova VB. Practice guidelines on correction of cardiovascular toxicity induced by chemotherapy and targeted agents. Zlokachestvennye opukholi. 2016;418-27 (In Russ.) doi:10.18027/2224-5057-2016-4s2-418-427.
6. Aleksin AA, Khoronenko VE, Pikin OV, Shemetova MM. The influence of factors of surgical aggression on the frequency of postoperative atrial fibrillation in patients with malignant lung tumors. Onkologiya. Zhurnal im. P. A. Gertsena. 2015;4(3):28-34. (In Russ.) doi:10.17116/onkolog20154328-34.
7. Khoronenko VE, Mandryka EA, Baskakov DS, Suvorin PA. Adjuvant cardioprotection in thoracic cancer surgery. Anesteziologiya i reanimatologiya. 2019;( 1):35-43. (In Russ.) doi: 10.17116/anaesthesiology201901135.
8. Guglin M, Aljayeh M, Saiyad S, et al. Introducing a new entity: chemotherapy-induced arrhythmia. Europace. 2009;11(12):1579-86. doi:10.1093/europace/eup300.
9. Ostenfeld EB, Erichsen R, Pedersen L, et al. Atrial fibrillation as a marker of occult cancer. PLoS One. 2014;9:e102861. doi:10.1371/journal.pone.0102861
10. Bagnes C, Panchuk PN, Recondo G. Antineoplastic chemotherapy induced QTc prolongation. Curr Drug Saf. 2010;5( 1 ):93-6. doi:10.2174/157488610789869111.
11. Horacek JM, Jakl M, Horackova J, et al. Assessment of anthracycline-induced cardiotoxicity with electrocardiography. Exp Oncol. 2009;31(2):115-7 doi:10.5507/bp.2014.004.
12. Numico G, Castiglione F, Granetto C, et al. Single-agent pegylated liposomal doxorubicin (Caelix®) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial. Lung Cancer. 2002;35:59-64. doi:10.1016/s0169-5002(01)00269-0.
13. Mazur M, Wang F, Hodge DO, et al. Burden of cardiac arrhythmias in patients with anthracycline-related cardiomyopathy. JACC Clin Electrophysiol. 2017;3(2):139-50. doi: 10.1016/j.jacep.2016.08.009.
14. Mileshkin LR, Seymour JF, Wolf MM, et al. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leuk Lymphoma. 2005;46(11):1575-9. doi:10.1080/10428190500235884.
15. Feliz V, Saiyad S, Ramarao SM, et al. Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin Cardiol. 2011;34(6):356-9. doi:10.1002/clc.20904.
16. Ulrickson M, Aldridge J, Kim HT, et al. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. Biol Blood Marrow Transplant. 2009; 15(11): 1447-54. doi: 10.1016/j.bbmt.2009.07.014.
17. 17 Yilmaz U, Oztop I, Ciloglu A, et al. 5-fluorouracil increases the number and complexity of premature complexes in the heart: a prospective study using ambulatory ECG monitoring. Int J Clin Pract. 2007;61(5):795-801. doi:10.1111/j.1742-1241.2007.01323.x.
18. Khan MA, Masood N, Husain N, et al. A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center. J Pak Med Assoc. 2012;62(5):430-4.
19. Gridelli C, Cigolari S, Gallo C, et al.; MILES Investigators. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer. 2001;31(3):277-84. doi:10.1016/s0169-5002(00)00194-x.
20. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as frontline therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008;112(5):1638-45. doi:10.1182/blood-2007-11-124602.
21. Buchholz S, Dammann E, Stadler M, et al. Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. Eur J Haematol. 2012;88(1):52-60. doi:10.1111/j.1600-0609.2011.01703.x.
22. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109-15. doi:10.1200/JCO.2006.10.2434.
23. Rathkopf DE, Picus J, Hussain A, et al. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer.Cancer Chemother Pharmacol. 2013;72(3):537-44. doi:10.1007/s00280-013-2224-8.
24. Noonan AM, Eisch RA, Liewehr DJ, et al. Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel. Clin Cancer Res. 2013;19(11):3095-104. doi:10.1158/1078-0432.ccr-13-0109.
25. Shah MH, Binkley P, Chan K, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2006;12(13):3997-4003. doi:10.1158/1078-0432.ccr-05-2689.
26. Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003;17(4):775-9. doi:10.1038/sj.leu.2402866.
27. Fahdi IE, Gaddam V, Saucedo JF, et al. Bradycardia during therapy for multiple myeloma with thalidomide. Am J Cardiol. 2004;93(8):1052-5. doi:10.1016/j.amjcard.2003.12.061.
28. Rajkumar SV, Rosinol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008;26(13):2171-7. doi:10.1200/jco.2007.14.1853.
29. Zellos L, Richards WG, Capalbo L, et al. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2009;137(2):453-8. doi:10.1016/j.jtcvs.2008.07.055.
30. Diwadkar S, Patel AA, Fradley MG. Bortezomib-induced complete heart block and myocardial scar: the potential role of cardiac biomarkers in monitoring cardiotoxicity. Case Rep Cardiol. 2016;2016:3456287. doi:10.1155/2016/3456287.
31. Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98(11):1753-61. doi:10.3324/haematol.2013.089334.
32. Morcos PN, Bogman K, Hubeaux S, et al. Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies. Cancer Chemother Pharmacol. 2017;79(3):559-68. doi:10.1007/s00280-017-3253-5.
33. Khozin S, Blumenthal GM, Zhang L, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res. 2015;21(11):2436-9. doi:10.1158/1078-0432.ccr-14-3157.
34. Ou SH, Tang Y, Polli A, et al. Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007). Cancer Med. 2016;5(4):617-22. doi:10.1002/cam4.622.
35. Tartarone A, Gallucci G, Lazzari C, et al. Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management. Future Oncol. 2015; 11(14):2043-8. doi: 10.2217/fon.15.47
36. Emelina EI, Gendlin GE, Nikitin IG, et al. Rhythm and Conduction Disorders in Patients Receiving Ibrutinib. Clinical oncohematology. 2019; 12(2):220-30. (In Russ.) doi: 10.21320/2500-2139-2019-12-2-220-230.
37. Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128(1):138-40. doi:10.1182/blood-2016-05-712828.
38. Lipsky AH, Farooqui MZ, Tian X, et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2015;100(12):1571-8. doi:10.3324/haematol.2015.126672.
39. Bello CL, Mulay M, Huang X, et al. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res. 2009;15(22):7045-52. doi:10.1158/1078-0432.ccr-09-1521.
40. Tolcher AW, Appleman LJ, Shapiro GI, et al. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2011;67(4):751-64. doi:10.1007/s00280-010-1372-3.
41. Petrini I, Lencioni M, Ricasoli M, et al. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2012;69(3):773-80. doi:10.1007/s00280-011-1753-2.
42. Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13(9):897-905. doi:10.1016/s1470-2045(12)70335-2.
43. Thornton K, Kim G, Maher VE, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U. S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2012; 18(14):3722-30. doi: 10.1158/1078-0432.ccr-12-0411.
44. Brahmer JR, Lacchetti C, Schneider J, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-68. doi:10.1200/jop.18.00005.
45. Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95. doi:10.1186/s40425-017-0300-z.
46. Heinzerling L, Ott PA, Hodi FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4:50. doi:10.1186/s40425-016-0152-y.
47. Behling J, Kaes J, Munzel T, et al. New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma. Melanoma Res. 2017; 27(2): 155-8. doi:10.1097/cmr.0000000000000314.
Review
For citations:
Potievskaya V.I., Akhobekov A.A., Kononova E.V. Relationship between cardiac arrhythmias and anticancer therapy. Cardiovascular Therapy and Prevention. 2020;19(5):2417. (In Russ.) https://doi.org/10.15829/1728-8800-2020-2417
Views:
667
Email this article 
